Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 2)
NCT05630820Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Bepirovirsen with Placebo (2 arms). Primary endpoint: Number of participants achieving functional cure (FC) with baseline HBsAg <=3000 IU/mL at 72 weeks. Started Dec 2022; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05630820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630820.